HNSCC is widely considered to be an EGFR-driven disease as its overexpression confers a poor prognosis39, Cetuximab is active in this disease, and most cell lines and many PDX models are sensitive to the growth inhibitory properties of cetuximab40. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.